Sign in
Taking people in United StatesNo phase

Ablation index guidance for ventricular tachycardia after heart attack damage

Tests ablation index guidance during ventricular tachycardia ablation in people with ischemic cardiomyopathy.

Key facts

Who runs it
Rush University Medical Center
Where
Ann Arbor, Boston, Charleston, Chicago, and Rochester, United StatesSee the 5 sites
Trial code
Registry title
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
Status
Recruiting
People taking part
100 people, planned
Started
23 Oct 2024
Expected to end
23 Nov 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ablation-index guided ventricular tachycardia ablation
  • Ventricular tachycardia ablation with no AI-guidance
Record updated
22 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart muscle damage from reduced blood flow (ischemic cardiomyopathy) who have scar-related ventricular tachycardia, a fast heart rhythm from the lower heart chambers.

Age
18 years and older
Sex
All sexes can join
Disease stage
Sustained scar-related monomorphic ventricular tachycardia, shown on an ECG or a check of an implanted heart device (CIED).
Earlier treatment
People who had VT substrate ablation in the previous 6 months cannot join.

Main reasons for not taking part

  • Main rhythm problem is mostly PVCs (extra heartbeats), supraventricular tachycardia or ventricular fibrillation
  • Heart attack or heart surgery within 6 months
  • Stroke or TIA (mini-stroke) within 6 months
  • Severe mitral valve leakage (mitral regurgitation)
  • Severe heart failure (NYHA class IV) or VT scar not caused by ischemia

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patient ≥ 18 y.o
  • Structural Heart Disease: Ischemic Cardiomyopathy
  • Sustained Scar-related Monomorphic Ventricular Tachycardia documented by ECG or CIED interrogation

Who cannot take part

  • Prior VT substrate ablation in the previous 6 months
  • If clinical ventricular arrhythmia is predominantly PVCs, supraventricular tachycardia, or ventricular fibrillation
  • Myocardial infarction or cardiac surgery within 6 months
  • Stroke or TIA within 6 months
  • Severe mitral regurgitation
  • NYHA functional class IV
  • Non-ischemic VT substrate

Where in United States

  • Medical University of MichiganAnn Arbor, United StatesContact: Jackson Liang, DONot yet recruiting
  • Mass General Brigham and Women's HospitalBoston, United StatesContact: Jorge E. Romero, MDNot yet recruiting
  • Medical University of South CarolinaCharleston, United StatesContact: Bishnu Dhakal, MDNot yet recruiting
  • Rush University Medical CenterChicago, United StatesContact: Henry D Huang, MDTaking people
  • Mayo ClinicRochester, United StatesContact: Konstantinos Siontis, MDNot yet recruiting

About the trial

What the trial wants to find out

Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. The investigators aim at conducting the first randomized controlled trial testing for the superiority of an AI-guided approach regarding procedural duration.

The 2 groups in the trial

  • AI-guided ablationTreatment being tested

    Use of AI guidance to conduct the ablation

    Treatment: Ablation-index guided ventricular tachycardia ablation

  • non-AI guided ablationExisting treatment, for comparison

    Ablation without AI guidance, AI values masked to the operator.

    Treatment: Ventricular tachycardia ablation with no AI-guidance

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy (AIM-VT) - a Prospective Single-Blinded, Multicenter Randomized Controlled Trial
Plain-language title
Ablation index guidance for ventricular tachycardia after heart attack damageGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
22 September 2025